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Introduction
Chronic  Myelo id  Leukaemia  (CML) i s  a 
myeloproliferative disorder but a definite mechanism 
leading to this carcinogenesis is not yet completely 
understood (Elharam Ibrahim Abd allah, 2017). It is 
known that environmental exposure to cytotoxic and 
genotoxic agents derived from benzene may be associated 
with increased risk of CML (Bajpai et al., 2007). And 
genetic susceptibility studies of CML may serve to identify 
populations at risk here, together with its important disease 
mechanisms (Elharam Ibrahim Abd allah, 2017).
The development of cancer results from an imbalance 
between exposure to carcinogens (endogenous and 
exogenous) and the capacity of various enzyme systems 
engaged in the activation or detoxification of Xenobiotics. 
Inter-individual genetic variation in xenobiotic 
metabolizing enzymes has been associated with cancer 
development, (Kassogue et al., 2015) and since such 
a metabolism constitutes an important line of defense 
against a variety of carcinogens, inherited differences in 
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the capacity of these enzymes may be an important genetic 
factor in cancer susceptibility (Ana Luisa, 2013). 
Xenobiotic metabolizing enzymes (XMEs) constitute 
one of the first lines of defence and they play a central 
role in the metabolism, elimination, and detoxification 
of xenobiotics or exogenous compounds introduced to 
the body (Omiecinski et al., 2011). Enzymes within the 
multiple enzyme system are classified in two categories 
namely Phase I and Phase II. The latter constitutes the 
theme of this study and its major detoxifying enzymes 
are Glutathione S-transferases (GSTs) which enable a 
wide variety of functions. GSTs fall into two distinct 
super-families: membrane bound microsomal GSTs and 
the soluble or cytosolic GSTs. Some genes of cytosolic 
enzymes play a crucial role in the detoxification of 
activated carcinogens and implications in cancer progress, 
particularly GSTP1, GSTM1, and GST1 (Sailaja et al., 
2010). Polymorphisms in these genes lead to the absence 
or decreased detoxification ability of enzymes, their 
dysfunction, and finally may impact on the risk of cancer 
development and heterogeneous drug responsiveness 
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(Rostami et al., 2019). 
GSTP1 gene possesses two variations in coding region, 
an A-to-G transition at105 codon and a C-to-T transition 
at 114 codon (Sailaja et al., 2010). The GSTP1 Ile105Val 
polymorphism at nucleotide 313 in exon 5 of GSTP1 lead 
to an amino acid substitution of isoleucine (Ile) by valine 
(Val) at amino acid position 105 (Ile105Val) (Dunna et al., 
2012). This substitution potentially diminished the ability 
to detoxify certain carcinogens which would induce DNA 
adducts, ultimately leads to carcinogenesis (Sailaja et al., 
2010). The frequency of the homozygous mutant genotype 
(Val/Val) ranged from 4% to 16% among White, 4% to 5% 
among Asian, and 19% for African-American ethnicities 
(Coughlin and Hall, 2002).
GSTM1 polymorphism has been identified with three 
alleles; GSTM1*0, GSTM1*A and GSTM1*B (Engel et 
al., 2002). The former is a null allele consisting of the 
complete deletion of the GSTM1 gene. Individuals who 
are homozygous for this allele are unable to produce the 
GSTM1 protein. The null variant of GSTΜ1 is of particular 
interest as a plethora of studies have demonstrated the 
difference in its susceptibility, exposure to environmental 
toxicants, and resistance to chemotherapy treatment 
(Rostami et al., 2019; Mondal et al., 2005; Bhat et al., 
2012). The frequency of the GSTM1 null genotype ranges 
from 23% to 48% in African populations, 33% to 63% in 
Asian populations, 39% to 62% in European populations, 
and 23% to 62% in U.S. populations (Coughlin and Hall, 
2002). 
The GSTT1 gene is polymorphic and has two alleles, 
the GSTT1*1 and the GSTT1*0 (Mir Muhammad 
NasirUddin, 2014). The former is an active allele, having 
a crucial role in the Phase-II biotransformation of a 
number of drugs and industrial chemicals. The latter is 
a non-functional allele arising from the deletion of the 
GSTT1 gene, with null GSTT1 (0/0) phenotype individuals 
being unable to form the GSTT1 protein (Bajpai et al., 
2007). The homozygous GSTT1 null phenotype has 
been described in different populations and shows wide 
variation (Bajpai et al., 2007; Rostami et al., 2019; Lordelo 
et al., 2012). The frequency of the GSTT1 null genotype 
has been described in different ethnic groups with varying 
degrees as follows: 22% to 29% in African-Americans, 
16% to 64% in Asian individuals, 15% to 27% in whites, 
10% to 21% in European populations and 10% to 12% in 
Mexican-Americans (Coughlin and Hall, 2002). Therefore 
these alleles and the previous ones have taken a place in 
this study. 
The association between GSTP1 Ile105Val, GSTM1 
and GSTT1 polymorphisms in the susceptibility to 
CML was investigated by different studies, but with 
conflicting results (Banescu et al., 2014; Lordelo et al., 
2012; Al-Achkar et al., 2014; Lourenco et al., 2005; 
Weich et al., 2016; Hishida et al., 2005; Bhat et al., 2012). 
Therefore, this study aimed to determine the frequency 
of genetic polymorphism in GST (P1, M1 and T1) genes 
and to ascertain their association with CML within the 
Sudanese population.
Materials and Methods
This cross-sectional, case-control study was conducted 
at the Radiation and Isotopes Center of Khartoum, (RICK). 
The study included 200 patients diagnosed with CML, 
68 (34%) females and 132 (66%) males plus 100 age 
matched healthy controls, 49 (49%) females and 51 (51%) 
males; 300 participants in total. All CML patients were in 
chronic phase with exception of one patient who was in 
an accelerated phase.
The Institutional Ethical Committee of Al-Neelain 
University approved the study and written consent was 
obtained from all the participants involved. Patients 
suffering from any other disease such as chronic 
myelomonocytic leukaemia and other myeloproliferative 
disorders were excluded. The control group consisted of 
healthy unrelated volunteers without a medical history 
of cancer and all patients and controls were of Sudanese 
ethnicity.
DNA extraction: Venous blood samples (3ml) were 
collected into EDTA containing vacutainers. Genomic 
DNA used for polymorphic analysis was extracted by 
guanidine chloride method and isolated DNA was stored 
in Tris EDTA buffer at -20°C till use.
GST P1 polymorphism: The genetic polymorphism 
analysis for GSTP1was determined by using the polymerase 
chain reaction/ restriction fragment length polymorphism 
(PCR/ RFLP) method. Primer pairs used were synthesized 
from Macrogen) F5′-ACCCCAGGGCTCTATGGGAA-3′ 
and R5′TGAGGGCACAAGAAGCCCCT-3′). 
A three-step PCR was standardized using Sensoquest 
thermocycler, involving initial denaturation at 95°C for 
3 min, followed by 35 cycles of denaturation at 94°C for 
30 sec, annealing at 61°C for 30 sec, and extension at 
72°C for 40sec – with a final extension at 72°C for 5 min.
Amplification products corresponding to 176bp were 
then visualized after electrophoresis in an ethidium-
bromide-stained 2% agarose gel and then subjected to 
restriction enzyme analysis with BsmA1 (New England 
BioLabsInc). 
Quantities 0.2 μl of BsmA1enzyme, 2 μl of enzyme 
buffer, 5 μl of the PCR product and 2.8 μl of double 
distilled water were then incubated overnight at 37°C. 
Three banding patterns were observed on 3% agarose 
gel stained with ethidium-bromide and these were; 176 bp 
bands corresponding to the AA (Ile/Ile, homozygous wild 
type genotype), 176, 91 and 85 bp bands corresponded to 
the AG (Ile/Val, heterozygous genotype) and 91, 85 bp 
bands that corresponded to the GG (Val/Val, homozygous 
mutant genotype).
GSTM1 and GSTT1 polymorphism: The polymorphic 
deletion of GSTM1 and GSTT1 genes were genotyped 
using the multiplex PCR approach. Primers used for 
GSTM1 and GSTT1 amplification were synthesized from 
Macrogen:  F5’-GAA CTC CCT GAA AAG CTA AAG 
C-3’; R5’-GTT GGG CTC AAA TAT ACG GTG G-3’ 
and F5’-TTC CTT ACT GGT CCT CAC ATC TC-3’, 
R5’-TCA CCG GAT CAT GGC CAG CA-3’, respectively. 
An 268-bp fragment of β-globin gene amplified 
by F5’-CAA CTT CAT CCA CGT TCA CC-3’, R5’- GAA 
GAG CCA AGG ACA GGT AC-3’ primers was used as 
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The frequency of individuals carrying the GSTM1 in 
patients and controls were 44% and 21.7% respectively. 
The GSTM1 null genotype frequency was found to 
be slightly higher in the control group, (35% as opposed 
to 34% in CML patients), but this difference was not 
considered to be statistically significant (OR =0.975, 95% 
CI: 0.578-1.584; p- value = 0.863).
GSTT1 was found in 57.5% of CML patients and 79% 
of the Control but the  frequency of individuals carrying 
the GSTT1 null genotype was significantly higher among 
CML patients, 42% compared to 21% of the Control; 
(OR =2.781, 95% CI: 1.593-4.853; p-value =0.000). 
The GSTT1 genotype presence may thus be considered a 
protective factor for CML.
The combined effects of GSTM1 and GSTT1 
genotypes in CML risk were also conducted. Individuals 
with a combined GSTM1 null/GSTT1 null genotype 
had an estimated 2.847-fold increased risk of CML 
over individuals with a GSTM1 present /GSTT1 present 
genotype (OR=2.847; CI=1.288-6.293; p-value=0.000). In 
contrast, the GSTM1 present /GSTT1 null and GSTM1 null/
GSTT1 present genotypes were not associated with a CML 
risk (p-value=0.064 and 0.061 respectively), see Table 2.
Discussion
Several previous studies have reported an association 
between the polymorphisms of the GSTs genes and the 
susceptibility of developing certain types of cancer. Such 
cancers include lung cancer (Mir Muhammad NasirUddin, 
2014), ovarian cancer (Coughlin and Hall, 2002) and 
breast cancer (Hashemi et al., 2012). Previous studies 
have reported about GSTs association with heamatological 
malignancy, but with conflicting findings as mentioned 
previously (Dunna et al., 2012; Zhou et al., 2013; Rostami 
internal positive control. 
The thermocycling procedure (Techne GeniusTC-412 
Thermal Cycler), involved initial denaturation at 94°C 
for 4 minutes, followed by 35 cycles of 1 minute at 
94 °C, 45 seconds at 55°C, 1 minute at 72°C and a final 
extension for 10 minutes at 72°C. Genotyping of the 
genes (null genotypes) is revealed by the absence of the 
219 bp for GSTM1 and 480 bp for GSTT1 PCR products. 
PCR products for the genotyping of polymorphisms 
were visualized by 2% agarose gel electrophoresis with 
ethidium bromide. The absence of β-globin amplification 
here indicated a failure of PCR reaction. 
Statistical analysis: Statistical analysis included 
descriptive statistics of the mean using standard deviation. 
The Odds ratio (OR) with a confidence interval (CI) of 
95% was calculated by logistic regression. Pearson’s 
chi-square test was then used to compare genotype 
distribution between patients and control, with p-values 
less than 0.05 being considered as statistically significant. 
Results
The distribution of the GSTP1, GSTM1 and GSTT1 
genotypes in CML patients and controls are shown 
in Table 1. The homozygous (Val/Val) of GSTP1, the 
heterozygous (Ile/Val) and the wild genotype of GSTP1 
(Ile/Ile) forms were found in 3.5%, 31.5% and 65% of 
CML cases, respectively.
In the Control, the homozygous (Val/Val) of 
GSTP1 Ile105Val, heterozygous (Ile/Val) and the wild 
genotype of GSTP1 (Ile/Ile) forms were 2%, 36% 
and 62%, respectively. The homozygous mutant type 
(Val/Val) showed no significant difference between 
patients and controls (OR=1.992, 95% CI: 0.396-9.322; 
P-value = 0.417).
Genotypes CML N (%) Control N (%) OR 95%CI P-value
GSTM1 GSTT1
Present Present 91 (45.5) 53 (53) Reference
Present Null 41 (20.5) (b) 12 (12) 1.99 0.96 - 4.12 0.064
Null Present 24 (12) (b) 26 (26) 0.54 0.28 - 1.03 0.061
Null Null 44 (22) (a) 9 (9) 2.85 1.29 - 6.29 0
N, total number; OR, odd ratio; CI, confidence interval; Statistical significance (P- value) is shown in superscript parenthesis; (a), <0.05; (b), >0.05. 
Table 2. Combination Effect of GSTM1 and GSTT1 Genotypes on CML Risk
Genotypes/ Allele frequency CML N (%) Control N (%) OR 95%CI P-value
GSTP1 AA 130 (65) 62 (62) Reference
AG 63 (31.5) (b) 36 (36) 0.84 0.51 - 1.40 0.505
GG 7 (3.5) (b) 2 (2) 1.99 0.40 - 9.32 0.417
A 323 (80.8) 160 (80) Reference
G 77 (19.3%)(b) 40 (20%) 1.05 0.68 - 1.61 0.827
GSTM1 Present 132 (66) 65(65) Reference
Null 68 (34) (b) 35(35) 0.98 0.58 - 1.58 0.863
GSTT1 Present 115 (57.5) 79(79) Reference
Null 85 (42) (a) 21(21) 2.781 1.59 - 4.85 0
N, total number; OR, odd ratio; CI, confidence interval; Statistical significance (P-value) is shown in superscript parenthesis; (a), <0.05; (b), >0.05 
Table 1. Distribution of GSTP1, GSTM1 and GSTT1 Genotypes in CML Patients and Control
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et al., 2019; Weich et al., 2016). In the present study, 3.5% 
of CML patients and 2% of the control had the homozygous 
type (Val/Val) of GSTP1 Ile105Val polymorphism. No 
significant difference was found between patients and 
the control and the study also revealed no association 
between GSTP1 Ile 105 Val polymorphism and the risk 
of developing CML:(OR=1.992, 95% CI: 0.396-9.322; 
p-value = 0.417). 
This finding was in agreement with a study conducted 
in Turkey by Karkucak et al who found no evidence 
between GSTP1Ile105Val and CML susceptibility 
(p-value 0.199) (Mutlu Karkucak, 2012). Weich and 
co-workers also reported no meaningful association 
between GSTP1Ile105Val and CML risk (Weich et al., 
2016). Several studies disagree with our findings in stating 
that there may be a relationship between GSTP1 Ile 105 
Val polymorphism and CML development/prognosis 
(Sailaja et al., 2010; Rostami et al., 2019; Banescu et al., 
2014). Some of these studies relied on smaller sample 
size and others on very broad confidence levels. Such 
contrary findings may also not have taken into account 
the geographical and ethnic differences in the type of 
environmental carcinogens samples the patients may have 
been exposed to (Sailaja et al., 2010; Banescu et al., 2014).
Homozygotes for the null allele (deletion) of GSTM1 
and GSTT1 lack the activity of respective enzymes. 
This makes the reactivity of electrophilic substrates 
low and therefore affects the function within cellular 
macromolecules. (Hashemi et al., 2012). The GSTM1 null 
and GSTT1 null appear to be associated with a significant 
risk of several types of cancers, such as hematological 
neoplasm (Banescu et al., 2014; Sailaja et al., 2010; Zhou 
et al., 2013) and breast cancer (Hashemi et al., 2012). It 
has been shown that the risk of ALL is doubled in patients 
who carry the GSTM1 deletion (Joseph et al., 2004). The 
GSTT1 null genotype was also demonstrated as a risk 
factor for both AML and ALL in some ethnic groups 
(Zhou et al., 2013).
Interestingly, no association between GSTM1 
null genotype and the risk of CML was found here: 
(OR =0.975, 95% CI: 0.578-1.584; p- value = 0.863). 
However, Muddathir and his co-workers found that 
GSTM1 null genotype was associated with increased risk 
of CML among Sudanese(Muddathir et al., 2019). This 
is not unexpected because Sudan is multiethnic with an 
admixture of Arab and African lineages which may be 
associated with differences in genetic makeup. The tribal 
differences within the participant populations in these 
two studies, irrespective of different in sample sizes, 
may contribute to this variation in the results. In contrast, 
Taspinar et al and Hishida et al claimed that GSTM1 
polymorphism was not associated with the risk of CML, 
which was in agreement with our study (Hishida et al., 
2005; Taspinar et al., 2008). Al-Achkar and co-workers 
however, concluded that GSTM1 null genotype was 
associated with increase risk of CML: (OR=2.55; 95% 
CI; 1.54-4.22; p-value = 0.0002) (Al-Achkar et al., 
2014). An interesting result was observed by Lordelo et 
al who found a positive association between CML risk 
with GSTM1 present genotype and that the GSTM1 null 
genotype decreased this risk (Lordelo et al., 2012). 
In the present study, we observed that the frequency 
of GSTT1  null genotype in CML patients was 
significantly higher than in the control (OR =2.781, 
95% CI: 1.593 - 4.853; p-value =0.000). GSTT1 null 
genotype frequency posed a 2.781 fold increase in the 
risk of CML, compared to those possessing both alleles. 
Therefore, the GSTT1 genotype may be a protective factor 
for CML, whilst the null genotype showed an association 
with the development of CML. The above findings were 
in agreement with a recent study conducted in Sudan 
(Muddathir et al., 2019). Many studies have focused 
on the relationship between GSTT1 polymorphism and 
the risk of CML in diverse ethnic groups (Bajpai et al., 
2007; Al-Achkar et al., 2014; Kassogue et al., 2015). 
These findings were in agreement with this study. In 
contrast however, a Japanese study reported no significant 
association between GSTT1 and the risk of CML 
(OR=1.32, 95% CI; 0.74-2.36; p-value= 0.353) (Hishida 
et al., 2005). 
GSTT1 is involved in the metabolism of ethylene 
oxide (EO) - a genotoxic agent capable of producing 
heritable translocations and increasing the frequency 
of spontaneous chromosome abnormality. Presuming 
that EO is higher in GSTT1 null individuals, it was 
hypothesized that the loss of the GSTT1 gene may be an 
influencing factor in the production of the Philadelphia 
chromosome (Ph) associated with CML (Lourenco et 
al., 2005). 
A combined analysis was conducted to assess the 
role of polymorphic variants on CML risk. We observed 
a significant interaction between the GSTM1 null and 
GSTT1 null genotypes, and thus, individuals carrying 
the null genotype of both are at a higher risk to CML: 
(OR=2.847; CI=1.288-6.293; p-value=0.000). It might be 
inferred from the data that the both genes (GSTM1 and 
GSTT1), act in a synergistic way and are important to the 
detoxification system (Bhat et al., 2012). When these genes 
lack their enzyme activity and become inactive there is an 
increased opportunity for DNA damage, resulting in the 
risk elevation of the double null genotype to CML (Ozten 
et al., 2012), as found in this study. The risk elevation of 
this double null genotypes was also in accordance with the 
Al-Achkar and co-worker study (Al-Achkar et al., 2014). 
Taspinar et al., (2008) also suggested that the association 
between the GSTT1 or GSTM1 genotype and CML 
depends on relative expression levels. Therefore the 
current result suggested a distinguished haplotype which 
was found with a higher susceptibility in having CML as 
detected in not many ethnic groups.
In the present study, it was not possible to compare 
GSTs polymorphism within the clinical phases of CML, 
because only one sample was found to be on accelerating 
phase with no blast crisis. However, A study has reported 
significant increases in the frequency of the GSTP1 mutant 
allele Val in the advanced disease state (accelerated and 
blast crises), as compared to the chronic phase (Sailaja 
et al., 2010). Furthermore, Lourenco et al reported the 
frequency of the GSTM1 null genotype being lower in 
patients in the accelerated phase or with blast crisis than 
those patients in the chronic phase:(20.0% vs. 49.0%, 
p-value 0.01) (Lourenco et al., 2005). In contrary, Bənescu 
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et al., (2014)  found no association between GSTM1 null 
or GSTT1 null and the clinical phases of CML. 
In conclusion, this study found that the percentage 
of the GSTT1 null genotype in CML patients was 
significantly higher than in the control and thus the GSTT1 
genotype may be assumed a protective factor for CML, 
with the null genotype associated with the development of 
this disease. Additionally, no association between GSTP1 
and GSTM1 and the susceptibility to CML was found. 
This study may provide a basis for further more extensive 
testing in a larger Sudanese population.
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